In this meta‐analysis, an aggregated OR of 3.20 (95% CI 2.04–5.04; analysis of 4266 cases and 5566 controls) was calculated for ATM, an aggregated OR of 3.25 (95% CI 2.55–4.13, analysis of 7263 cases and 13,785 controls) was calculated for CHEK2, and an aggregated OR of 21.40 (95% CI 10.10–45.32, analysis of 5862 cases and 17,453 controls) was calculated for PALB2. Based on a recent analysis of a large series of BC patients of European ancestry, Couch et al. This evidence concerns the gene PALB2 and breast cancer.